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Dear Editor,
We read with no surprise the letter of Ruiz-Argü elles about our recently published contribution in this journal. 1 He pointed out that the first description about factor V (FV) Leiden in a Mexican indigenous population was done in 1996; it is true. 2 In fact, this report strongly encouraged us to perform our research because it was done in a very small sample of individuals from 1 single ethnic group living in our country. Because almost 10 million Mexican indigenous live in Mexico, this research was not enough to have an epidemiological knowledge about FV Leiden in this specific population. However, it seems that Ruiz-Argü elles did not understand the very essence of our paper. He claims that the description of the low incidence of FV Leiden was done in one of his papers. 3 However, this descriptive research was performed in a very small, nonsignificant sample of patients with primary thrombophilia. He claims that derived from his results (in thrombophilic populations), ''it is clear that the prevalence of the FV Leiden mutation in Mexican Indians and/or mestizos is very low.'' It seems that the statement of Ruiz-Argü elles lacks congruency because in his publications prevalence of FV Leiden widely varies from 4% to 11%. [3] [4] [5] [6] . On the contrary, our research was done in a truly representative sample of healthy individuals from the whole Mexican Republic. Of course, the wide prevalence range of FL Leiden reported by Ruiz-Argü elles is totally different to that found in our investigation (0.85%).
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